Bulk cytotoxic T lymphocytes (CTL) were generated by in vitro stimulation of BMT donor lymphocytes with Philadelphia chromosome (Ph)-positive leukemic cells from an HLA-identical sibling patient. CTL were cytotoxic against the patient's leukemic cells as well as the EBV-lymphoblastoid cell line (EBV-LCL) generated from the patient's cells, suggesting that they recognize a minor histocompatibility antigen (mHAg). Subsequently, several CTL lines were established by a limiting dilution method and analyzed. One of these CTL lines, 16C12 CTL which used a single TCR␤V3S1 for CD8 cells, lysed HLA-A31-positive leukemic cells and EBV-LCL, but not fibroblasts. The cytotoxicity against the patient's leukemic cells and EBV-LCL was blocked by anti-HLA-A31 moAb, anti-HLA-class I moAb, and anti-CD8 moAb, suggesting that this mHAg was presented with HLA-A31. The antigen recognized by 16C12 CTL seemed to be a novel mHAg, since HLA-A31 restricted antigen has not been reported to date and 16C12 CTL showed no cytotoxicity against EBV-LCL which probably express known mHAgs. CTL detecting this mHAg may play an important role in the GVL effect in HLA-A31-positive BMT patients. Keywords: minor histocompatibility antigen; GVL; CTL; BMT The GVL effect has been considered to be very important in preventing leukemia relapse after bone marrow transplantation (BMT). [1] [2] [3] [4] [5] From this point of view, donor leukocyte infusion (DLI) was introduced to CML patients and ALL patients with relapse after BMT, with promising results.
Materials and methods

Patient
The patient was a 12-year-old girl with Philadelphia chromosome (Ph)-positive (minor BCR-ABL) ALL. Cell surface markers on the leukemic cells were CD10, CD13, CD19, CD34 and HLA-DR. She (HLA-A31,A24; B35,B52;Cw3,-; DR15,DR15; DRB1 *1501,*1502) received an allogeneic BMT from an HLA-identical brother, TW without GVHD. She successfully received several DLIs from TW to prevent relapse after BMT without GVHD or myelosuppression, because of the persistent BCR-ABL chimeric mRNA detected by the reverse transcriptase (RT)-PCR method after BMT. 18 Bulk CTL culture A bulk CTL culture was established by stimulating 1 × 10 5 BMT donor PBL with 1 × 10 5 of 35 Gy irradiated patient's leukemic cells in a 96-well round-bottomed microtiter plate and suspended in RPMI 1640 plus 15% pooled human AB serum and 10 mm HEPES. On day 6, 1 × 10 5 viable cells were restimulated with 1 × 10 6 irradiated leukemic cells, and 2% highly purified IL-2 (Biotest, Dreieich, Germany) in a 24-well flat-bottomed culture plate. From day 14, cultures were restimulated and expanded weekly with 1 × 10 6 irradiated leukemic cells and 20% T cell growth factor (TCGF; Biotest). Allogeneic CTL were induced from unrelated PBL, which shared no HLA with the patient, stimulated with patient's leukemic cells and maintained using the same method as described above.
Limiting dilution of bulk CTL
A bulk CTL culture was cloned by a limiting dilution method on day 6 after the 5th stimulation. One, 2, 4, 8, and 16 blastic cells/well were expanded in RPMI 1640 plus 15% human serum, 10 mm HEPES, 100 IU/ml human recombinant IL-2 (Takeda Chemical Industries, Osaka, Japan), and 10% TCGF (Biotest) in a 96-well roundbottomed mictotiter plate. Feeder cells contained 2 × 10 4 of 20 Gy irradiated donor's PBL and 2 × 10 4 of 35 Gy irradiated patient's leukemic cells. From day 8, cultures from each well were expanded and restimulated weekly with 2 × 10 4 irradiated donor's PBL and 2 × 10 4 irradiated patient's leukemic cells under the same conditions as described above.
Target cells
Leukemic cells were collected and frozen in liquid nitrogen until use. Frozen leukemic cells were thawed 1 day before a chromium release assay and cultured with 10 ng/ml human tumor necrosis factor-␣ (TNF-␣; Boehringer Mannheim, Mannheim, Germany) overnight in order to increase the sensitivity to a chromium release assay as reported by Dolstra et al. 16 EBV-LCL from the patient was established from PBL at diagnosis by infection with EBV of B95-8 in the presence of 800 ng/ml cyclosporin A (Sandoz Industries, Basel, Switzerland). PHA blasts were generated from PBL at diagnosis by stimulating PBL with 1% PHA-M (Difco Laboratories, Detroit, MI, USA) for 3 days. PHA blasts were further cultured with 10% TCGF for 3-4 days and were frozen in liquid nitrogen. HLA-A31-positive and/or HLA-B35-positive EBV-LCLs were obtained from Mr Kenichi Ohya, Aichi Red Cross Blood Center, Seto, Japan. The patient's bone marrow fibroblasts were established from the bone marrow at diagnosis.
Chromium release assay
Target cells except fibroblasts were incubated with 100 Ci of Na 2
51
CrO 4 (CSJ-11; Amersham Japan, Tokyo, Japan) at 37°C for 1 h. Fibroblasts were labelled with 200 Ci of Na 2
CrO 4 for 18 h. 19 Labelled cells were washed three times with RPMI 1640 with 2% FCS. After spinning down at 50 g for 1 min, 5 × 10 3 leukemic cells, EBV-LCL, and PHA blasts were incubated with CTL line at different effector to target (E/T) ratios for 4 h. Fibroblasts were incubated with CTL for 8 h. After incubation, the supernatant was collected using the Supernatant Harvesting System (Skatron Instruments, Tranby, Norway) and the radioactivity of supernatant was counted for 1 min using a ␥ scintillation counter. Spontaneous release was measured by incubation of target cells in the absence of effector cells, and maximum release was determined by lysing the target cells in 2.5% Triton-X 100 (Sigma, St Louis, MO, USA). The percentage of specific lysis was calculated as follows: 100 × (experimental mean c.p.m. Ϫ spontaneous release mean c.p.m.)/(maximum release mean c.p.m. Ϫ spontaneous release mean c.p.m.). In a cold target cell inhibition experiment, mixtures of non-radioactive (cold) and 51 Cr-labelled (hot) target cells at different ratios were incubated with CTL line at fixed E/T ratio.
Blocking of cytotoxicity by moAbs
moAbs (anti-CD3, -CD4, -CD8) were added and incubated for 30 min at 37°C until target cells were added. Anti-HLA class I and anti-HLA class II moAbs were added just before the addition of target cells and incubated for 20 min at 37°C. Thereafter, a chromium release assay was conducted as described above. moAbs used were anti-CD3 ( 
TCR␤V gene expression on 16C12 CTL line
Total RNA was prepared from 16C12 CTL according to the method of Chomczynski and Sacchi 21 using a commercially available kit (Stratagene, La Jolla, CA, USA). The entire RNA content was subjected to synthesis of cDNA by M-MLV RT (GibcoBRL, Gaithersburg, MD, USA) and primer p(dT)15 (Boehringer Mannheim). PCR reactions were carried out on a GeneAmp PCR system 9600 (Perkin Elmer, Foster City, CA, USA) in a 20 l of volume with appropriate amount of cDNA from the line as previously described. 22 Briefly, each reaction mixture contained one of 24 TCR␤V family-specific primers, 500 m dNTPs, 1.5 mm MCl 2 , 1 unit AmpliTaq Gold DNA polymerase (Perkin Elmer) in 1 × buffer. The PCR conditions were as follows: one cycle of 94°C for 9 min, followed by 35 cycles of 94°C for 30 s; 58°C for 30 s; 72°C for 30 s, and finally one cycle of 72°C for 10 min. The amplified PCR products were size fractionated on 2.2% mini-agarose gels (Mupid II; Cosmo Bio, Tokyo, Japan). The DNA fragments were excised and purified with a kit (QlAquick Gel Extraction Kit; Qiagen, Santa Clara, CA, USA). Direct DNA sequencing was performed using BC primer used in the PCR with Thermo Sequenase (Amersham, Cleveland, OH, USA). For TCR expression, 16C12 CTL was analyzed by FACScan using anti-CD4-PE (Becton Dickinson), anti-CD8-PE (Becton Dickinson), TCRV␤ 3-FITC (Beckman Coulter, Miami, FL, USA) and TCRV␤ 5.1-FITC (Beckman Coulter).
Results
Generation of bulk CTL
A bulk CTL culture was initiated by stimulating BMT donor PBL with the HLA-identical patient's leukemic cells and then stimulated weekly with the leukemic cells. The bulk CTL showed only weak cytotoxicity against the patient's leukemic cells, but strong cytotoxicity against the leukemic cells pretreated with TNF-␣ and against EBV-LCL of patient origin, but not against donor EBV-LCL or K562, a standard target for NK activity, suggesting that the antigen detected is a mHAg rather than a leukemia-specific antigen ( Figure 1a ). The lysis of the patient's PHA blasts by the bulk CTL was not observed. The cytotoxic activity of bulk CTL was increased by repeated stimulations. The lysis of TNF-␣ pretreated leukemic cells by the bulk CTL was inhibited by anti-CD3, -CD8 and HLA class I moAbs, but not by anti-CD4 and HLA class II moAbs ( Figure 1b ). The lysis of patient-derived EBV-LCL was also inhibited by anti-CD8 and HLA class I moAbs, suggesting that HLA class I-restricted CD8 cells in the bulk CTL have cytotoxic activity against TNF-␣ pretreated leukemic cells and EBV-LCL.
Limiting dilution of bulk CTL
The growth efficiency of of 16, 8, 4, 2, 1 cells/well was 42%, 24%, 13%, 18% and 3%, respectively. About 60% of the lines showed cytotoxicity against both the patient's leukemic cells pretreated with TNF-␣ and patient-derived EBV-LCL, but not against donor-derived EBV-LCL, similarly to the bulk CTL. Six CTL lines, showing relatively good growth, were analyzed for the phenotype (Table 1 ). All CTL lines were TCR␣␤ positive and TCR␥␦ negative. 1F8 and 16E3 were CD8 cell dominant, while 8H9 and 16B6 were CD4 cell dominant. 16C12 and 2E12 were mixed with CD4 and CD8 cells.
Cytotoxicity of CTL lines
CD8 cell dominant, 1F8 and 16E3, lines showed cytotoxicity against the patient's TNF-␣ pretreated leukemic cells and patient-derived EBV-LCL, but not against donorderived EBV-LCL or K562. These two showed no cytotoxicity against the patient's PHA blasts (Figure 2a, b) . CD4 cell dominant, 8H9 and 16B6, lines killed patient-derived EBV-LCL, but showed weak cytotoxicity against the patient's TNF-␣ pretreated leukemic cells (Figure 2e, f) . 16C12 and 2E12 lines of mixed CD4 and CD8 cells showed strong cytotoxicity against the patient's TNF-␣ pretreated leukemic cells and patient-derived EBV-LCL. 16C12 line showed cytotoxicity against the patient's PHA blasts, whereas 2E12 did not (Figure 2c, d) . 16C12 line showed constant growth and killing activity, whereas other CTL lines did not. Accordingly, 16C12 line was further analyzed in the subsequent study.
TCR␤V gene analysis of 16C12 CTL line
Attempts were made to establish a 16C12 clone consisting of only CD8 cells, but were not successful. So, TCR␤V gene expression on CD8 cells was studied. By RT-PCR, two cDNA clones, TCR␤V3S1 and TCR␤V5S1, were obtained from the 16C12 CTL line consisting of CD4 and CD8 cells. 16C12 CTL cells were analyzed by FACS using PE-conjugated anti-CD8 moAb, PE-conjugated anti-CD4 moAb, FITC-conjugated anti-TCR␤V3S1 moAb, and TCR␣␤  85  94  82  86  82  95  TCR␥␦  0  0  0  0  0  0  CD3  97  99  99  99  98  97  CD4  8  2  39  40  97  99  CD8  96  99  72  82  10  1  CD2  99  100  100  100  100  100  CD28  3  8  28  34  64  50  CD11b  57  86  88  59  57  76  HLA-DR  97  99  100  100  99  99   a Percentage of positive cells was detected by a flow cytometer. FITC-conjugated anti-TCR␤V5S1 moAb. The two-color analysis showed that most of CD8-positive cells expressed TCR␤V3S1, suggesting that 16C12 CTL was monoclonal ( Figure 3 ).
Antibody blocking experiment of 16C12 CTL
The lysis of TNF-␣ pretreated leukemic cells by 16C12 CTL was inhibited by anti-CD3, -CD8, and HLA-class I moAbs, but not by anti-CD4 and HLA class II moAbs (Figure 4) . The lysis of patient-derived EBV-LCL was also inhibited by anti-CD3, -CD8 and HLA class I moAbs, suggesting that CD8, but not CD4, cells of 16C12 CTL lysed TNF-␣ pretreated leukemic cells and EBV-LCL by recognizing an antigen presented by HLA class I.
Cytotoxicity of 16C12 CTL against EBV-LCL derived from the patient's family
We tested the cytotoxicity of 16C12 CTL against EBVLCLs derived from the patient's family. It lysed patientand father-derived EBV-LCL, but not donor-EBV-LCL, brother-EBV-LCL or mother-derived EBV-LCL ( Table 2 ), suggesting that 16C12 CTL recognizes a mHAg on the patient's leukemic cells and EBV-LCL presented by HLA-A31, HLA-B35 or HLA-Cw3.
Cold target cell inhibition experiment of 16C12 CTL
Cold target cell inhibition experiments were performed with EBV-LCLs from the patient's family to study the specificity ( Figure 5 ). Unlabelled patient's EBV-LCL and father's EBV-LCL, both of which were sensitive to 16C12 CTL, inhibited the lysis of radiolabelled patient-derived EBV-LCL by 16C12 CTL, but not EBV-LCLs of donor, brother and mother origin.
HLA restriction of cytotoxicity of 16C12 CTL
Since the cytotoxicity of 16C12 CTL against EBV-LCLs derived from the family members suggested the restriction by HLA-A31, -B35 or -Cw3, it was tested against unrelated EBV-LCLs expressing these HLA allotypes. Besides patient-derived EBV-LCL, 16C12 CTL showed clear cytotoxicity against two EBV-LCLs (SPL, KM) and weak cytotoxicity against three EBV-LCLs (HT, MM, SN). All the EBV-LCLs were found to express HLA-A31, suggesting the HLA-A31 restriction of 16C12 CTL (Table 3) .
Anti-HLA-A31 moAb blocking experiment of 16C12 CTL
Fortunately, mouse anti-HLA-A31 moAb was available 20 for an antibody blocking experiment ( Figure 6 ). The lysis of patient's TNF-␣ pretreated leukemic cells, patientderived EBV-LCL, and an unrelated HLA-A31-positive Table 2 ). EBV-LCL (SPL), which was sensitive to 16C12 CTL, was strongly inhibited by anti-HLA-A31 moAb, confirming the HLA-A31 restriction of this CTL activity.
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B62 Cw1/Cw10 DR8 0 Ϯ 0.6 0 Ϯ 0.7 JHAF A31 B51 Cw8 DR4 2 Ϯ 0.5 1 Ϯ 0.6 KM A31/A24 B35/B61 Cw3/Cw8 DR4/DR8 26 Ϯ 2.2 11 Ϯ 1.7 MM A31/A11 B54/B61 Cw1/Cw8 DR4/DR8 9 Ϯ 0.9 4 Ϯ 2.0 YN A31/A24 B35/B7 Cw3/Cw7 DR1/DR9 1 Ϯ 3.8 0 Ϯ 1.8 SN A31/A2 B35/B46 Cw3/Cw1 DR8/DR9 8 Ϯ 1.4 8 Ϯ 1.7 AM A31/A26 B61/B70 Cw1 DR8/DR14 0 Ϯ 1.9 0 Ϯ 0.3 RH A31/A11 B59/B61 Cw3/Cw1 DR4/DR4 0 Ϯ 2.4 0 Ϯ 1.5 HU A24/A26 B35/B7 Cw3/Cw7 DR15/DR1 0 Ϯ 3.8 0 Ϯ 1.9 HM A26/A26 B35/B7 Cw3/Cw7 DR15/DR1 0 Ϯ 1.3 0 Ϯ 2.7 JO528239 A1 B35 Cw4 DR11 0 Ϯ 3.5 0 Ϯ 2.2 BM9 A2 B35 Cw4 DR8 0 Ϯ 1.4 0 Ϯ 1.5 KOSE A2 B35 ND DR13/DR14 0 Ϯ 1.4 0 Ϯ 1.4 WT100BIS A11 B35 Cw4 DR1 1 Ϯ 0.9 1 Ϯ 0.9 KT-17 A2/A11 B35/B62 Cw4/Cw9 DR4 0 Ϯ 1.0 0 Ϯ 2.3 TISI A24 B35 Cw4 DR11 0 Ϯ 0.5 0 Ϯ 0.8 EHM A3 B35 Cw4 DR1 0 Ϯ 1.2 0 Ϯ 0.9 HS A2/A26 B35/B7 Cw3/Cw7 DR1/DR4 0 Ϯ 1.6 0 Ϯ 0.6 ND = not detected.
Lysis of leukemic cells by 16C12 CTL
We next examined whether or not 16C12 CTL can lyse HLA-A31-positive TNF-␣ pretreated leukemic cells from other patients. Three out of eight HLA-A31-positive ALLs, including the patient's own leukemic cells, were killed by 16C12 CTL (Table 4) , although it showed no cytotoxicity against five AML and one acute monocytic leukemia (AMoL) samples.
No lysis of patient's fibroblasts by 16C12 CTL
To determine whether 16C12 antigen is expressed on fibroblasts, we initiated a fibroblast culture from the patient's bone marrow aspirate at diagnosis and then examined it. Although allogeneic CTL, which were generated from unrelated PBL which shared no HLA-A, -B, -DR, showed strong killing against patient's fibroblasts, ie 60% at E/T ratio of 20 and 32% at E/T ratio of 2, 16C12 CTL did not show significant killing against fibroblasts (4.8% at E/T ratio of 2). The susceptibility of fibroblasts to CTL killing was not induced by 10 ng/ml TNF-␣ pretreatment for 48 h (Figure 7 ). Fibroblasts were also examined after treatment with 10 ng/ml TNF-␣ for 48 h. Allogeneic CTL (Allo CTL) were generated as described in Materials and methods, and used as controls. The E/T ratio for 16C12 CTL ( ) was 2:1, and for allogeneic CTL () was 20:1.
Discussion
In the present study, we succeeded in generating CTL detecting a mHAg on hematopoietic cells by stimulating BMT donor lymphocytes with HLA-identical leukemic cells. As a responder cell population, the BM mononuclear cells from the BMT donor or the donor-derived PBL in the recipient have been used by various investigators, [12] [13] [14] [15] [16] [17] but in this study, we showed that the naive PBL from BMT donor can be used to generate primary in vitro CTL responses against leukemic cells in HLA-identical sibling pairs. The primary purpose of this study was to generate CTL detecting a leukemia-specific antigen and to use the CTL thus generated for the treatment of the patient with minimal residual disease and possibly overt relapse after BMT. Obviously, it is very important to generate such CTL from donor PBL before BMT. Smit et al 23 also reported that leukemic-reactive CTL were generated from HLA-identical donors PBL of patients with CML using a limiting dilution assay, although they did not analyze the mHAg possibly detected by the CTL. We assumed that donor T cells are better than the donor-derived T cells in the recipient because the former is an immunologically healthy population and that the latter may be induced to be tolerant to a leukemia antigen in the recipient under immunosuppressive treatment. It is, however, also conceivable that the latter may be sensitized by a leukemia antigen in the recipient, leading to the effective generation of CTL against leukemic cells. Further study is necessary to elucidate this interesting question.
In this study, we reported the mHAg detected by HLA-A31-restricted 16C12 CTL. HLA-A31, with which this mHAg was presented, is one of the A3-like alleles, and the phenotypic frequency in Japanese, Caucasian, Black, Chinese and Hispanic is 14.8%, 4.4%, 3.8%, 9.6% and 10.1%, respectively. 24 So far, more than 30 human mHAgs detected by CD8 or CD4 T cells have been reported and among these, H-Y, HA-1 and HA-2 antigens have been defined with respect to their genes and antigenic peptides. [25] [26] [27] At present, it is difficult to compare the 16C12 antigen in this study with other reported mHAgs, but the following evidence supports that 16C12 antigen is new: (1) no subtype of HLA-A31 has been found, 28 suggesting that 16C12 antigen is not related to a subtype of HLA-A31, but a mHAg presented by HLA-A31. (2) HLA-A31 restricted mHAg has not been reported. (3) H-Y antigen should not be detectable in the combination of male donor responder cells and female recipient leukemia cells as we employed. (4) 16C12 CTL was not cytotoxic against EBV-LCL expressing HLA-A1(0/4), -A2.1(0/5), -B7(0/6) and/or B35(1/14), -B38(0/2), -B44(0/3); many of these lines probably express a variety of known mHAgs when their population frequency is high. 9 (5) Maruya et al 29 recently reported that the incompatibility of CD62L and CD62L + CD49b was associated with acute GVHD in Japanese patients with HLA-A3-like superfamily including HLA-A31. A preliminary study by Maruya and Saji showed that patient-derived EBV-LCL and donor-derived EBV-LCL had the same polymorphisms of CD49b and CD62L, sug-gesting that these adhesion molecules are not likely to be the target antigens which 16C12 CTL detected.
With regard to tissue distribution, the 16C12 antigen is expressed on leukemia cells, EBV-LCL and PHA blasts, but not on fibroblasts, like many of the mHAgs so far reported. [12] [13] [14] [15] [16] [17] The 16C12 antigen is expressed in 4/15 HLA-A31 + EBV-LCLs including those of the patient's family members and 3/8 HLA-A31
+ common ALL, suggesting the population frequency is not high, although further testing of PHA blasts from volunteers is necessary to estimate this. In addition, various types of HLA-A31
+ normal and malignant hematopoietic cells, and non-hematopoietic cells need to be tested in order to determine the tissue distribution of this antigen. Since technologies are now available for defining the genes and antigenic peptides corresponding to the antigens detected by CTL, as has been reported for mHAgs and tumor-specific antigens, a similar study will be initiated with 16C12 CTL.
Leukemia relapse after allogeneic BMT is still a serious problem. If we can consistently generate mHAg-specific CTL from PBL of BMT donors before BMT, adoptive immunotherapy using such CTLs to mHAg which are selectively or predominantly expressed on leukemic cells, may be useful for the treatment and protection from relapse of high risk leukemia patients with HLA-A31 after BMT.
